Wikisage, the free encyclopedia of the second generation, is digital heritage
Amifampridine: Difference between revisions
Jump to navigation
Jump to search
(→ATC) |
(→ATC) |
||
| Line 3: | Line 3: | ||
==ATC== | ==ATC== | ||
https://www.whocc.no/atc_ddd_index/?code=N07XX05 | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
<gallery>File:3,4-diaminopyridine-3D-balls.png</gallery> | <gallery>File:3,4-diaminopyridine-3D-balls.png</gallery> | ||
: [[wikipedia:amifampridine|Amifampridine]] | |||
<ref>[http://www.whocc.no/atc_ddd_index/?code=N07XX05 N07XX05]</ref></center> | |||
|} | |||
==Links== | ==Links== | ||
Revision as of 00:24, 7 May 2019
Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS [1])[2]
ATC
https://www.whocc.no/atc_ddd_index/?code=N07XX05
Links
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder Drug Trial Snapshot: Firdapse
